A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2.
Qian ZhangRenpeng ZhouJingjing YangChanglin DouTianyi GanFujia LiuBaihui HuDeyong SongChao LuWei HuPublished in: Infectious diseases and therapy (2021)
ClinicalTrial.gov Identifier NCT04973735.